A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder

Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Sirukumab (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Dec 2017 Planned End Date changed from 31 May 2018 to 8 Jun 2018.
    • 12 Dec 2017 Planned primary completion date changed from 16 Oct 2017 to 31 May 2018.
    • 22 Sep 2017 Planned End Date changed from 16 Apr 2018 to 31 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top